Advertisement
Screener

Oruka Therapeutics, Inc. (ORKA) EBITDA

Oruka Therapeutics, Inc. EBITDA

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of the cash a company's operations generate before accounting charges for wearing out its assets. Here it is operating income plus the filed depreciation and amortization, not a figure the company adjusted itself. Higher EBITDA means more operating profit before those charges. It is not an official accounting (GAAP) measure and does not subtract capital spending, interest or tax, so it does not show what those obligations cost.

  • Oruka Therapeutics, Inc. ebitda for the quarter ending 2026-06-30 was -$50.06M, a change of -$21.65M year-over-year.
  • Oruka Therapeutics, Inc. ebitda for the quarter ending 2026-03-31 was -$36.39M, a change of -$11.32M year-over-year.
  • Oruka Therapeutics, Inc. ebitda for the quarter ending 2025-12-31 was -$34.4M.
  • Oruka Therapeutics, Inc. ebitda for the quarter ending 2025-09-30 was -$34.09M.
  • Oruka Therapeutics, Inc. ebitda for fiscal 2025 was -$121.97M.
  • Oruka Therapeutics, Inc. ebitda for fiscal 2023 was -$7.28M, a change of $3.3M from fiscal 2022.
  • Oruka Therapeutics, Inc. ebitda for fiscal 2022 was -$10.58M, a change of $8.74M from fiscal 2021.
  • Oruka Therapeutics, Inc. ebitda for fiscal 2021 was -$19.32M, a change of -$9.56M from fiscal 2020.
Available history
2010-09-30 to 2026-06-30
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported-$50.06M-$50.11M$43,000.00(m)(m)$0.00*-$33.15M*(m)$43.26M(m)(m)
2026-03-31Reported-$36.39M-$36.43M$43,000.00(m)(m)$73.00K-$23.58M(m)$29.14M(m)(m)
2025-12-31Reported-$34.4M-$34.43M$28,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2025-09-30Reported-$34.09M-$34.11M$20,000.00(m)(m)$99.00K*-$21.60M*(m)$28.99M(m)(m)
2025-06-30Reported-$28.41M-$28.43M$19,000.00(m)(m)$34.00K*-$23.14M*(m)$24.09M(m)(m)
2025-03-31Reported-$25.07M-$25.09M$16,000.00(m)(m)$13.00K-$20.87M(m)$19.93M(m)(m)
2024-09-30Reported(m)-$29.45M(m)(m)(m)(m)(m)(m)$25.69M(m)(m)
2024-06-30Reported-$21.49M-$21.49M$3,000.00(m)(m)(m)-$2.63M*(m)$18.67M(m)(m)
2024-03-31Reported-$2.48M-$2.48M$3,000.00(m)(m)(m)-$1.53M(m)$165.00K(m)(m)
2023-12-31Reported-$1.59M-$1.59M$3,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$1.93M-$1.94M$4,000.00(m)(m)(m)-$1.67M*(m)$322.00K(m)(m)
2023-06-30Reported-$1.97M-$1.97M$4,000.00(m)(m)(m)-$694.00K*(m)$254.00K(m)(m)
2023-03-31Reported-$1.79M-$1.8M$4,000.00(m)(m)(m)-$1.59M(m)$390.00K(m)(m)
2022-12-31Reported-$1.54M-$1.55M$5,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2022-09-30Reported-$2.55M-$2.55M$4,000.00(m)(m)$0.00*-$2.50M*(m)$1.02M(m)(m)
2022-06-30Reported-$3.21M-$3.22M$6,000.00(m)(m)$0.00*-$2.62M*(m)$1.49M(m)(m)
2022-03-31Reported-$3.27M-$3.28M$5,000.00(m)(m)$2.00K-$4.30M(m)$2.18M(m)(m)
2021-12-31Reported-$5.68M-$5.68M$5,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2021-09-30Reported-$4.71M-$4.72M$5,000.00(m)(m)$14.00K*-$4.87M*(m)$3.44M(m)(m)
2021-06-30Reported-$4.83M-$4.84M$3,000.00(m)(m)$16.00K*-$3.72M*(m)$3.58M(m)(m)
2021-03-31Reported-$4.1M-$4.1M$3,000.00(m)(m)$6.00K-$5.22M(m)$2.88M(m)(m)
2020-12-31Reported-$5.12M-$5.13M$2,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2020-09-30Reported-$1.99M-$1.99M$2,000.00(m)(m)$0.00*-$2.00M*(m)$1.05M(m)$0.00*
2020-06-30Reported-$1.31M-$1.31M$1,000.00(m)(m)$3.00K*-$1.04M*(m)$372.00K(m)-$9.00K
2020-03-31Reported-$1.34M-$1.34M$3,000.00(m)(m)$3.00K-$1.69M(m)$365.00K(m)(m)
2019-12-31Reported-$1.28M-$1.28M$2,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2019-09-30Reported-$1.24M-$1.25M$5,000.00(m)(m)(m)-$887.00K*(m)$347.00K(m)-$42.00K
2019-06-30Reported-$1.5M-$1.51M$6,000.00(m)(m)(m)-$1.19M*(m)$440.00K(m)-$27.00K
2019-03-31Reported-$1.78M-$1.78M$5,000.00(m)(m)(m)-$1.57M(m)$662.00K(m)-$82.00K
2018-12-31Reported-$1.52M-$1.53M$5,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2018-09-30Reported-$1.66M-$1.66M$6,000.00(m)(m)$3.00K*-$1.58M*(m)$740.00K(m)-$31.00K
2018-06-30Reported-$2.15M-$2.16M$5,000.00(m)(m)$0.00*-$2.25M*(m)$1.15M(m)(m)
2018-03-31Reported-$2.77M-$2.77M$6,000.00(m)(m)$1.00K-$3.07M(m)$1.72M(m)(m)
2017-12-31Reported-$4.29M-$4.3M$6,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2017-09-30Reported-$4.47M-$4.48M$7,000.00(m)(m)$0.00*-$3.97M*(m)$3.49M(m)(m)
2017-06-30Reported-$5.55M-$5.56M$7,000.00(m)(m)(m)(m)(m)$4.51M(m)(m)
2017-03-31Reported-$4.37M-$4.38M$7,000.00(m)(m)(m)(m)(m)$3.25M(m)(m)
2016-12-31Reported-$4.29M-$4.29M$7,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2016-09-30Reported-$4.7M-$4.71M$8,000.00(m)(m)$6.00K*(m)(m)$3.72M(m)(m)
2016-06-30Reported-$3.94M-$3.94M$4,000.00(m)(m)$1.00K*(m)(m)$2.91M(m)(m)
2016-03-31Reported-$3.66M-$3.67M$5,000.00(m)(m)$1.00K(m)(m)$2.59M(m)(m)
2015-12-31Reported-$3.17M-$3.18M$5,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2015-09-30Reported-$2.81M-$2.82M$5,000.00(m)(m)$2.00K*(m)(m)$1.72M(m)(m)
2015-06-30Reported-$2.71M-$2.72M$5,000.00(m)(m)$5.00K*(m)(m)$1.75M(m)(m)
2015-03-31Reported-$2.74M-$2.74M$4,000.00(m)(m)$2.00K(m)(m)$1.71M(m)(m)
2014-12-31Reported-$2.61M-$2.61M$4,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2014-09-30Reported-$2.28M-$2.29M$3,000.00(m)(m)$0.00*(m)(m)$1.33M$950.00K$0.00
2014-06-30Reported-$2.4M-$2.41M$2,000.00(m)(m)(m)(m)(m)$1.40M$1.01M(m)
2014-03-31Reported-$2.39M-$2.39M$3,000.00(m)(m)(m)(m)(m)$1.31M$1.08M(m)
2013-12-31Reported-$2.95M-$2.95M$2,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2013-09-30Reported-$1.72M-$1.73M$5,000.00(m)(m)$11.00K*-$1.68M*(m)$714.00K$1.01M$0.00
2013-06-30Reported-$1.19M-$1.2M$9,000.00(m)(m)$8.00K*-$976.00K*(m)$246.00K$952.00K(m)
2013-03-31Reported-$1.06M-$1.07M$10,000.00(m)(m)$9.00K-$764.00K(m)$181.00K$889.00K(m)
2012-12-31Reported-$830,000.00-$839,000.00$9,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2012-09-30Reported-$918,000.00-$928,000.00$10,000.00(m)(m)$0.00*-$775.00K*(m)$156.00K$772.00K(m)
2012-06-30Reported-$1.14M-$1.15M$10,000.00(m)(m)(m)-$977.00K*(m)$322.00K$823.00K(m)
2012-03-31Reported-$1.39M-$1.41M$14,000.00(m)(m)(m)-$1.66M(m)$422.00K$984.00K(m)
2011-12-31Reported-$1.55M-$1.63M$84,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2011-09-30Reported-$1.5M-$1.82M$323,000.00(m)(m)$0.00*-$1.68M*(m)$533.00K$1.29M(m)
2011-06-30Reported-$1.59M-$1.7M$114,000.00(m)(m)$0.00*-$2.11M*(m)$497.00K$1.21M(m)
2011-03-31Reported-$2.12M-$2.2M$81,000.00(m)(m)$1.00K-$1.94M(m)$690.00K$1.51M(m)
2010-12-31Reported-$2.27M-$2.35M$83,000.00(m)(m)(m)(m)(m)(m)(m)(m)
2010-09-30Reported-$2.02M-$2.11M$84,000.00(m)(m)$0.00*-$2.01M*(m)$726.00K$1.38M(m)
2010-06-30Reported(m)-$2.27M(m)(m)(m)(m)(m)(m)$700.00K$1.57M(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported-$121.97M-$122.05M$83,000.00(m)(m)$209.00K-$88.21M(m)$100.64M(m)(m)
2023-12-31Reported-$7.28M-$7.3M$15,000.00(m)(m)$0.00-$5.01M(m)$1.01M(m)$0.00
2022-12-31Reported-$10.58M-$10.6M$20,000.00(m)(m)$2.00K-$10.91M(m)$4.75M(m)$0.00
2021-12-31Reported-$19.32M-$19.34M$16,000.00(m)(m)$43.00K-$18.76M(m)$13.83M(m)$0.00
2020-12-31Reported-$9.76M-$9.77M$8,000.00(m)(m)$19.00K-$7.72M(m)$4.99M(m)-$9.00K
2019-12-31Reported-$5.8M-$5.81M$18,000.00(m)(m)$4.00K-$4.80M(m)$1.83M(m)-$167.00K
2018-12-31Reported-$8.1M-$8.12M$22,000.00(m)(m)$4.00K-$8.24M(m)$4.24M(m)-$31.00K
2017-12-31Reported-$18.69M-$18.71M$27,000.00(m)(m)$3.00K-$17.47M(m)$14.08M(m)-$61.00K
2016-12-31Reported-$16.59M-$16.61M$24,000.00(m)(m)$12.00K(m)(m)$12.35M(m)$0.00
2015-12-31Reported-$11.44M-$11.46M$19,000.00(m)(m)$11.00K(m)(m)$7.06M(m)$0.00
2014-12-31Reported-$9.68M-$9.69M$12,000.00(m)(m)$19.00K(m)(m)$5.63M(m)$0.00
2013-12-31Reported-$6.91M-$6.94M$26,000.00(m)(m)$32.00K-$5.29M(m)$2.93M$4.01M$0.00
2012-12-31Reported-$4.28M-$4.32M$43,000.00(m)(m)(m)-$4.08M(m)$1.09M$3.23M(m)
2011-12-31Reported-$6.76M-$7.36M$602,000.00(m)(m)$19.00K-$6.96M(m)$2.31M$5.05M(m)
2010-12-31Reported-$8.84M-$9.18M$338,000.00(m)(m)$4.00K-$8.32M(m)$3.11M$6.07M(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
Erasca, Inc. (ERAS)United States$5.073B-19.96
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Liquidia Corp (LQDA)United States$6.347B51.23
Veradermics, Inc (MANE)United States$4.839B